Phase 2b trial results of novel TB regimen show potential to shorten treatment

A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial. PaMZ is a three-drug regimen: pretomanid (Pa), moxifloxacin (M) and pyrazinamide (Z). The therapy is intended for those patients whose TB infections are sensitive to the three drugs, including people with drug-sensitive and multidrug-resistant TB (MDR-TB).The results of this trial show the potential for the PaMZ regimen to improve treatment for tuberculosis.
Source : www.sciencedaily.com      2015/3/30 10:49

خانه چاپ ارسال به دوستان نسخه متنی کوچک کردن متن بزرگ کردن متن دانلود خروجی پی دی اف خروجی میکروسافت ورد
0/10 (تعداد آرا 0 نفر )
Copyright © 2011 AASM. All Rights Reserved.